Abigail Mawer
Publications and Insights
- Publication: The commercial case for investing in ALS
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Publication: Employer Costs from Respiratory Infections
- Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
- Publication: The Cost of Drug Shortages
- Insight: Drug shortages are on the rise – but what is their impact?
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Insight: Rare Disease Day 2024: Why Do We Care About Rare?
- Publication: The Dynamics of Drug Shortages
- Insight: The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Bulletin: The Inflation Reduction Act has landed
- Insight: The US Inflation Reduction Act: What Do the Experts Think?
- Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: Payment Models for Multi-Indication Therapies
- Publication: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
- Publication: Indication-Based Pricing (IBP) Consultation Report
- Publication: Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
- Publication: Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
- Publication: Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
- Publication: Making Outcome-Based Payment a Reality in the NHS
- Publication: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
- Publication: Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
- Publication: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Publication: Data Governance Arrangements for Real-World Evidence: South Korea
- Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
- Publication: Improving Efficiency and Resource Allocation in Future Cancer Care
- Publication: “New Age” Decision Making in HTA: Is It Applicable in Asia?
- Publication: How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
- Publication: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
- Publication: Data Governance Arrangements for Real-World Evidence
- Publication: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
- Publication: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
- Publication: Exploring the Interdependencies of Research Funders in the UK